APA

Atallah E., Nussenzveig R., Yin C. C., Bueso-Ramos C., Tam C., Manshouri T., Pierce S., Kantarjian H. & Verstovsek S. (20080626). Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. : Leukemia.

Chicago

Atallah E, Nussenzveig R, Yin C C, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H and Verstovsek S. 20080626. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. : Leukemia.

Harvard

Atallah E., Nussenzveig R., Yin C. C., Bueso-Ramos C., Tam C., Manshouri T., Pierce S., Kantarjian H. and Verstovsek S. (20080626). Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. : Leukemia.

MLA

Atallah E, Nussenzveig R, Yin C C, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H and Verstovsek S. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. : Leukemia. 20080626.